相关实验视频
Updated: Jun 29, 2025

07:44
A Porcine Model of Acute Autologous Pulmonary Embolism
Published on: September 6, 2024
358
高风险或中等风险肺栓塞的导管治疗:死亡和重新住院
Orly Leiva1, Carlos Alviar1, Sameer Khandhar2,3
1Division of Cardiology, Department of Medicine, New York University Grossman School of Medicine, 550 First Ave, New York, NY 10016, USA.
European heart journal
|April 4, 2024
概括
导管治疗 (CBT) 减少了肺栓塞 (PE) 的住院死亡和90天再入院. 这项研究强调了CBT.
科学领域:
- 心血管医学 心血管医学
- 干预性肺病学 干预性肺病学
- 健康 结果 研究 研究 结果
背景情况:
- 肺栓塞 (PE) 治疗决策对于中等和高风险患者来说是具有挑战性的.
- 对于这些PE风险群体的导管治疗 (CBT) 有有限的数据.
- 这项研究评估了大量患者登记中的CBT结果.
研究的目的:
- 为了比较治疗PE患者的住院和再入院结果与没有CBT治疗的PE患者.
- 根据PE风险分层分析结果 (中等与高).
- 为PE管理的临床决策提供信息.
主要方法:
- 2017-2020年国家再接收数据库的回顾性分析.
- 包括住院患有中等风险或高风险PE的患者.
- 应用治疗权重的反向概率 (IPTW) 来调整基线差异.
- 评估住院死亡,出血和30/90天所有原因,VTE相关和出血相关的再入院情况.
主要成果:
- 在高风险 (OR 0.83) 和中等风险PE (OR 0.76) 两种情况下,CBT与住院死亡的几率显著降低.
- 用CBT治疗的高风险PE患者显示,90天所有原因 (HR 0.77) 和VTE再入院 (HR 0.46) 的风险较低.
- 接受CBT治疗的中等风险PE患者也表现出90天所有原因 (HR 0.75) 和VTE复发率 (HR 0.66) 的降低.
结论:
- 导管治疗与高风险和中等风险PE患者的生存率提高和再入院减少有关.
- 这些发现表明CBT是这些患者群体的有益治疗选择.
- 建议通过前性随机试验进行进一步验证,以确认这些结果.
相关概念视频
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
206
Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
206
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
162
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
162
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
159
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
159
Endoscopic Studies II: Thoracocentesis
258
Thoracentesis(Thoracocentesis), commonly known as pleural tap, is a medical procedure where a 22 gauge needle is inserted into the pleural space, the area between the lung and chest wall. This procedure is commonly performed to diagnose or treat various respiratory disorders.
Description
Excess pleural fluid or air may accumulate in some respiratory disorders in the thoracic cavity. To treat pleural effusion, a physician conducts thoracentesis by carefully piercing the chest wall and entering...
Description
Excess pleural fluid or air may accumulate in some respiratory disorders in the thoracic cavity. To treat pleural effusion, a physician conducts thoracentesis by carefully piercing the chest wall and entering...
258

